Please assess the completion status of the following clinical trial:

Trial Title: Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be 18 years of age and provide written informed consent and sign the HIPAA form~* Must have history of allergic rhinitis~* Must have positive response to Allergen BioCube~Key Exclusion Criteria:~* Must not have a significant illness such as moderate to severe allergic asthmatic reactions~* Must not have compromised lung function~* Must not use any disallowed medications~* Must not have been in an investigational study in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasapaque Nasal Solution (Type: EXPERIMENTAL): 250 ul in each nostril at Day 1 and Day 8
- Placebo Saline Nasal Solution (Type: ACTIVE_COMPARATOR): 250 ul in each nostril at Day 1 and Day 8

Based on this trial design, predict the completion outcome and termination type (if applicable).